Prophylactic pegfilgrastim support with adjuvant docetaxel, doxorubicin and cyclophosphamide (TAC) in node-positive breast cancer patients

被引：0
|
作者：
Rifa, Juli [1 ]
Del Alba, A. Gonzalez [1 ]
Perello, A. [1 ]
Alarcon, J. [1 ]
Avella, A. [1 ]
机构：
[1] Hosp Son Dureta, Palma De Mallorca, Spain
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [31] Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer
    Martin, M.
    Mackey, J.
    Pienkowski, T.
    Rolski, J.
    Guastalla, J-P
    Sami, A.
    Glaspy, J.
    Juhos, E.
    Wardley, A.
    Fornander, T.
    Hainsworth, J.
    Coleman, R.
    Modiano, M.
    Vinholes, J.
    Pinter, T.
    Childs, B.
    Roessner, M.
    Wilson, V.
    Rupin, M.
    Vogel, C.
    CANCER RESEARCH, 2010, 70
  • [32] Dose-dense (DD) two-weekly docetaxel/doxorubicin/cyclophosphamide (TAC) with G-CSF support compared to standard adjuvant TAC in breast cancer patients
    Latifzadeh, S. Z.
    Salimi, M.
    Naghnaeian, M.
    Entezari, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal
    Chilcott, J.
    Jones, M. Lloyd
    Wilkinson, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 7 - 13
  • [34] A multicenter pilot study of adjuvant docetaxel, epirubicin and cyclophosphamide (TEC) in patients (p) with stage II/III and node-positive breast cancer (BC)
    Mayordomo, J. I.
    Lorenzo, A.
    Modolell, A.
    Alvarez, I.
    Bayo, J.
    Machengs-M Centelles-K Villadiego, I.
    Rubio, M. J.
    Heras, L.
    Yubero, A.
    Gonzalvez, M. L.
    Valero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer.: Results from the GEPARTRIO study
    von Minckwitz, G.
    Kuemmel, S.
    du Bois, A.
    Eiermann, W.
    Eidtmann, H.
    Gerber, B.
    Hilfrich, J.
    Huober, J.
    Costa, S. D.
    Jackisch, C.
    Grasshoff, S. -T.
    Vescia, S.
    Skacel, T.
    Loibl, S.
    Mehta, K. M.
    Kaufmann, M.
    ANNALS OF ONCOLOGY, 2008, 19 (02) : 292 - 298
  • [36] Safety analysis of docetaxel (T) and doxorubicin (A) followed by sequential capecitabine (X) as adjuvant chemotherapy of patients with node-positive operable breast cancer (BC).
    Mayordomo, JI
    Madroñal, C
    Garcia-Lopez, MJ
    Burillo, MA
    Perez, V
    Janariz, J
    Murillo, L
    Andres, R
    Lara, R
    Lambea, J
    Sanz, IAJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 80S - 80S
  • [37] ADJUVANT CHEMOHORMONAL THERAPY WITH CYCLOPHOSPHAMIDE, DOXORUBICIN AND 5-FLUOROURACIL (CAF) WITH OR WITHOUT MEDROXYPROGESTERONE ACETATE FOR NODE-POSITIVE BREAST-CANCER PATIENTS
    HUPPERETS, PSGJ
    WILS, J
    VOLOVICS, L
    SCHOUTEN, L
    FICKERS, M
    BRON, H
    SCHOUTEN, HC
    JAGER, J
    SMEETS, J
    DEJONG, J
    BLIJHAM, GH
    ANNALS OF ONCOLOGY, 1993, 4 (04) : 295 - 301
  • [38] A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy
    Byeong Seok Sohn
    Jae Ho Jeong
    Jin-Hee Ahn
    Kyung Hae Jung
    Jeong Eun Kim
    Joo Hyuk Sohn
    Su-Jin Koh
    Jae Hong Seo
    Keun Seok Lee
    Sung-Bae Kim
    Investigational New Drugs, 2020, 38 : 866 - 873
  • [39] Phase II randomized adjuvant trial of dose-dense docetaxel (DOC) before or after doxorubicin/cyclophosphamide (AC) in axillary node-positive breast cancer.
    Puhalla, S.
    Young, D.
    Ottman, S.
    McVey, A.
    Kendra, K.
    Mrozek, E.
    Rhodes, C.
    Merriman, N. J.
    Knapp, M.
    Patel, T.
    Thompson, M. E.
    Maher, J. F.
    Moore, T. D.
    Shapiro, C. L.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S115 - S116
  • [40] A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy
    Sohn, Byeong Seok
    Jeong, Jae Ho
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Kim, Jeong Eun
    Sohn, Joo Hyuk
    Koh, Su-Jin
    Seo, Jae Hong
    Lee, Keun Seok
    Kim, Sung-Bae
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 866 - 873
12345